Talk:Adalimumab

Behcet's disease
Should Behcet's disease be added, or added under the heading of Uveitis? Disclaimer, I am not a medical brain, and am suggesting this on the talk page because I take it for BD, understand many others do and understand there is quite a bit of literature on this. So, I'm obviously not the right person to make a change to the article. I was thinking a sentence of two with citations could be added to the Uveitis part along the lines of "For example, uveitis associated with Behcet's disease". But not sure if that is on or off label use. Could some smarter people than me suggest whether this addition is warranted and the appropriate way to do it.
 * 
 * 
 * SiJoHaAl (talk) 07:50, 11 October 2020 (UTC)

Golimumab not listed?
Simponi, aka golimumab, was recently approved, making four TNF inhibitors... Ronabop (talk) 05:19, 26 April 2009 (UTC)

Marketing material
This article reads in places like marketing material for this Medication, "Adalimumab, like its TNF inhibitor competitors, infliximab, etanercept, certolizumab pegol and golimumab, has proven versatile in its effectiveness in treating several conditions." this is not encyclopedic or is it? I'd try a slightly more neutral tone --Triple5 (talk) 10:19, 4 February 2014 (UTC)

SK2016's edits - Oct 2014
User SK2016 made the following edits to the article https://en.wikipedia.org/w/index.php?title=Adalimumab&diff=632251910&oldid=628090398

This was SK2016's first edit, apparently for a class assignment. He/she worked on it for 2 days and never came back.

I left a message on SK2016's talk page https://en.wikipedia.org/wiki/User_talk:SK2016 about what I thought were the problems with the edit, but SK2016 never responded.

Basically, SK2016 eliminated a good summary, copied a lot from the package insert (instead of secondary sources), and made a lot of other changes that we don't use according to WP:MEDMOS.

I suggest reverting it back to the original version before SK2016's edits.

Any objections? --Nbauman (talk) 13:31, 14 November 2014 (UTC)


 * (It was reverted 21 Nov 2014)

Do biosimilars like expemtia have same molecular formula etc
Do biosimilars like Expemtia, ABP 501 have same molecular formula etc as Humira ? Are either decorated with sugars ? Do we plan to cover all biosimilars in the article about the original biologic ? - Rod57 (talk) 14:45, 15 June 2016 (UTC)

Biosimilars now available in EU (but not USA) - Competition
eg. says Novartis and Amgen biosimilars (to Humira) are now available across Europe. Also says some companies have agreed with AbbVie to not market their adalimumab biosimilars in USA until 2023. - Rod57 (talk) 09:12, 11 November 2018 (UTC)

Now, in 2023, around 8 biosimilar competitors are due to enter the market this year. . Could mention under Marketing, or perhaps better start a Competition section ? - Rod57 (talk) 02:25, 23 January 2023 (UTC)

Removed image
The image in the infobox is just a cartoon rendering of a generic IgG. It contains no features or details specific to adalimumab, and I can find no link to adalimumab in the image page on Commons. I have removed it from this article because it doesn't add any particular value. TenOfAllTrades(talk) 21:51, 2 August 2022 (UTC)

TenOfAllTrades, I would have kept the image even though it's a generic image. I think one should only cautiously delete images, if they are not replaced with something else. I came looking for an image and would have been happy with that of a generic IgG. 82.147.226.240 (talk) 22:44, 25 September 2023 (UTC)

NYT story on price, patents
The New York Times story by Robbins cited in the article is a major story about how the price of Humera (adalimumab) has risen to >$80,000 a year, which makes it unaffordable to patients without good health insurance. This is as a result of a patent strategy that was designed to "make it ore difficult for a biosimilar to follow behind," according to an AbbVie executive. For example, in 2014, AbbVie got a patent for a method of treating ankylosing spondylitis with a 40 milligram dose, adding 11 years of patent protection. There are many articles in WP:RS and WP:MEDRS about pricing and patents, which are hardly mentioned in this entry. I think it should go in. Any objections? Nbauman (talk) 18:53, 28 January 2023 (UTC)